HTFL
What one share of Heartflow holds
Surgical and Medical Instruments and Apparatus
We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide.
Heartflow’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.76 |
|---|---|
| Profit | −$1.54 |
| Capex (buildings and equipment) | $0.09 |
| Free cash flow | −$0.77 |
| Cash and investments | $0.40 |
| Book value | $3.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $17.84 | −$25.32 | $1.25 | −$16.90 | — | −$159.17 |
| 2024 | $23.46 | −$17.98 | $0.81 | −$13.68 | — | −$140.39 |
| 2025 | $4.78 | −$3.17 | $0.14 | −$1.60 | — | $3.53 |